Name and surname:
|
doc. MUDr. Richard Imrich, DrSc.
|
Document type:
|
Research/art/teacher profile of a person
|
The name of the university:
|
Comenius University Bratislava
|
The seat of the university:
|
Šafárikovo námestie 6, 818 06 Bratislava
|
III.a - Occupation-position | III.b - Institution | III.c - Duration |
---|---|---|
researcher | Institute of Experimental Endocrinology, now Biomedical Research Center | 2001-continues |
center coordinator, general director (2017-2022) | National Institute of Rheumatic Diseases | 2012-2023 |
university teacher - associated professor | Faculty of Medicine, Comenius University Bratislava | 2014-2017 |
university teacher - associated professor | Faculty of Medicine, Slovak Medical University Bratislava | 2019-2023 |
university teacher - associated professor | Faculty of Medicine, Comenius University Bratislava | 2023-continues |
V.1.a - Name of the profile course | V.1.b - Study programme | V.1.c - Degree | V.1.d - Field of study |
---|---|---|---|
Physiology | General medicine | I. | General medicine |
Physiology | Dentistry | I. | Dentistry |
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, Loftus N, Bygott H, Cox TF, Davison AS, Dillon JP, Fisher M, FitzGerald R, Genovese F, Glasova H, Hall AK, Hughes AT, Hughes JH, Imrich R, Jarvis JC, Khedr M, Laan D, Le Quan Sang KH, Luangrath E, Lukáčová O, Milan AM, Mistry A, Mlynáriková V, Norman BP, Olsson B, Rhodes NP, Rovenský J, Rudebeck M, Santucci A, Shweihdi E, Scott C, Sedláková J, Sireau N, Stančík R, Szamosi J, Taylor S, van Kan C, Vinjamuri S, Vrtíková E, Webb C, West E, Záňová E, Zatkova A, Gallagher JA.Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2020 Sep;8(9):762-772.
Ranganath LR, Milan AM, Hughes AT, Davison AS, M K, Norman BP, Bou-Gharios G, Gallagher JA, Imrich R, Arnoux JB, Rudebeck M, Olsson B. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria. Sci Rep. 2022 Sep 27;12(1):16083
Imrich R, Sedláková J, Úlehlová M, Gornall M, Jackson R, Olsson B, Rudebeck M, Gallagher J, Lukáčová O, Mlynáriková V, Stančík R, Vrtíková E, Záňová E, Zaťková A, Arnoux JB, Rovenský J, Luangrath E, Bygott H, Khedr M, Ranganath LR.Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone. RMD Open. 2022 Oct;8(2):e002422.
Cant HEO, Chatzidaki I, Olsson B, Rudebeck M, Arnoux JB, Imrich R, Eddowes LA, Ranganath LR. Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index. JIMD Rep. 2022 May 10;63(4):361-370.
Olsson B, Ranganath L, Arnoux JB, Imrich R, Milan A, Rudebeck M. Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria. JIMD Rep. 2021 Nov 9;63(1):41-49.
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, Loftus N, Bygott H, Cox TF, Davison AS, Dillon JP, Fisher M, FitzGerald R, Genovese F, Glasova H, Hall AK, Hughes AT, Hughes JH, Imrich R, Jarvis JC, Khedr M, Laan D, Le Quan Sang KH, Luangrath E, Lukáčová O, Milan AM, Mistry A, Mlynáriková V, Norman BP, Olsson B, Rhodes NP, Rovenský J, Rudebeck M, Santucci A, Shweihdi E, Scott C, Sedláková J, Sireau N, Stančík R, Szamosi J, Taylor S, van Kan C, Vinjamuri S, Vrtíková E, Webb C, West E, Záňová E, Zatkova A, Gallagher JA.Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2020 Sep;8(9):762-772.
Ranganath LR, Milan AM, Hughes AT, Davison AS, M K, Norman BP, Bou-Gharios G, Gallagher JA, Imrich R, Arnoux JB, Rudebeck M, Olsson B. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria. Sci Rep. 2022 Sep 27;12(1):16083
Imrich R, Sedláková J, Úlehlová M, Gornall M, Jackson R, Olsson B, Rudebeck M, Gallagher J, Lukáčová O, Mlynáriková V, Stančík R, Vrtíková E, Záňová E, Zaťková A, Arnoux JB, Rovenský J, Luangrath E, Bygott H, Khedr M, Ranganath LR.Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone. RMD Open. 2022 Oct;8(2):e002422.
Cant HEO, Chatzidaki I, Olsson B, Rudebeck M, Arnoux JB, Imrich R, Eddowes LA, Ranganath LR. Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index. JIMD Rep. 2022 May 10;63(4):361-370.
Olsson B, Ranganath L, Arnoux JB, Imrich R, Milan A, Rudebeck M. Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria. JIMD Rep. 2021 Nov 9;63(1):41-49.
Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, Srbecky M, Imrich R, Kyselovicova O, Belan V, Jelok I, Wolfrum C, Klimes I, Krssak M, Zemkova E, Gasperikova D, Ukropec J, Ukropcova B.Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014 Mar 1;592(5):1091-107. 311 citácií
Radikova Z, Koska J, Huckova M, Ksinantova L, Imrich R, Vigas M, Trnovec T, Langer P, Sebokova E, Klimes I.Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes. 2006 May;114(5):249-56. 131 citácií
Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, Imrich R, Conant S, Eldadah BA. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord. 2008 Dec;14(8):600-7. 137 citácií
Ranganath LR, Milan AM, Hughes AT, Dutton JJ, Fitzgerald R, Briggs MC, Bygott H, Psarelli EE, Cox TF, Gallagher JA, Jarvis JC, van Kan C, Hall AK, Laan D, Olsson B, Szamosi J, Rudebeck M, Kullenberg T, Cronlund A, Svensson L, Junestrand C, Ayoob H, Timmis OG, Sireau N, Le Quan Sang KH, Genovese F, Braconi D, Santucci A, Nemethova M, Zatkova A, McCaffrey J, Christensen P, Ross G, Imrich R, Rovensky J. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis. 2016 Feb;75(2):362-7. 107 citácií
Bertok T, Klukova L, Sediva A, Kasák P, Semak V, Micusik M, Omastova M, Chovanová L, Vlček M, Imrich R, Vikartovska A, Tkac J.Ultrasensitive impedimetric lectin biosensors with efficient antifouling properties applied in glycoprofiling of human serum samples. Anal Chem. 2013 Aug 6;85(15):7324-32. 80 citácií
FP7-HEALTH-2013-INNOVATION-1 Clinical Development of Nitisinone for Alkaptonuria (DevelopAKUre) 2012-2019, EudraCT 2012-005340-24, EudraCT 2013-001633-41, koordinátor centra
APVV-15-0228 Sclerosis multiplex - Úloha mitochondriálnej dysfunkcie v inzulinovej rezistencii, Multiple sclerosis - The role of mitochondrial dysfunction in insulin resistance. ClinicalTrials.gov Identifier: NCT03052595, zodpovedný riešiteľ, 2015-2019
MZ-2018/37-LFUK-11 The use of GLP-1 analogs in the multiple sclerosis treatment (MSGLP) 2018-2021, ClinicalTrials.gov Identifier: NCT01444833, spoluriešiteľ
APVV-21-0261 Účinky GLP-1 analógu na sclerosis multiplex, Effects of GLP-1 Analog on Multiple Sclerosis (GAMS) 2022-2026
ERA4Health, Fostering a European Research Area for Health Research (HORIZON-HLTH-2022-DISEASE-03), INSTITUTO DE SALUD CARLOS III (ISCIII), Spain, 2022-2029, Role: Co-investigator
VIII.a - Name of the institution | VIII.b - Address of the institution | VIII.c - Duration (indicate the duration of stay) | VIII.d - Mobility scheme, employment contract, other (describe) |
---|---|---|---|
Free University of Brussels | Brusel, Belgicko | 01/2004-05/2004 | Grant EULAR |
National Institutes of Health | Bethesda, MD, USA | 01/2005-01/2008 | NIH visiting fellow |
National Institutes of Health | Bethesda, MD, USA | 01/2008-01/2015 | NIH Guest Researchers |